Open Label, Single Dose, Non-randomized Study to Assess the Drug to Drug Interaction of Briakinumab on CYP Substrates.

NCT01260844 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

12

Enrollment

INDUSTRY

Sponsor class

Stopped Study stopped

Conditions

Moderate to Severe Plaque Psoriasis

Interventions

DRUG: briakinumab

Sponsor

Abbott